Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

NCT00321646 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Adenocarcinoma of the Prostate

Interventions

DRUG: Bevacizumab
DRUG: Docetaxel

Sponsor

Mary-Ellen Taplin, MD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]